Atezolizumab, which is a humanized monoclonal anti–programmed death ligand 1 (PD-L1) antibody, inhibits PD-L1–programmed death 1 (PD-1) and PD-L1–B7-1 signaling and restores tumor-specific T-cell immunity [17]. This evidence concerns the gene CD274 and neoplasm.